Company intelligence / Profile preview

Global Road Runner

Ownership: Private
Development stage: Other

Overview

Roadrunner Therapeutics is developing next-generation precision oncology drugs using advanced modalities such as targeted protein degraders, bispecific ADCs, and DACs. The company focuses on overcoming drug resistance and targeting undruggable proteins in solid tumors. Its pipeline includes multiple preclinical programs with an accelerated timeline toward IND filings starting in 2027. No clinical results are available yet.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateTargeted protein degraderDegrader antibody conjugate (DAC)Bispecific monoclonal antibody
Industry: Biotech

Partnerships

none disclosed

Beyond the preview

Go deeper on Global Road Runner.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global Road Runner.

Explore the full profile